Search results for: Precision Medicine

Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?

1 February 2017

…approach for assessing regenerative medicines, but rather to test whether regenerative medicines could fit into the existing pathway developed for conventional medicines. The authors suggest a more interesting question would…

Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS

29 August 2018

OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS. This OHE Consulting Report, published today, reviews “Measurement of Medicines Expenditure in the…

The WHO Technical Report on the Pricing of Cancer Medicines: Missing a Central Role for Value Assessment

8 April 2019

…key to efficient pricing and use of cancer medicines. The Research Paper outlines some for addressing these shortcomings. A new OHE Research Paper by Simon Brassel, Olga Rozanova, and Adrian…

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

17 March 2020

Adrian Towse presented evidence that transparency of process reduced corruption and improved competition. Evidence was, however, against price transparency for on-patent medicines. It will reduce access in low income countries….

Advancing Rare Disease Care: Challenges and Key Issues

28 February 2025

…had an expressed goal of improving access to rare disease medicines, with most applying special considerations for orphan medicine reimbursement. However, rare disease medicines without orphan designations are typically not…

2022 Innovation Policy Prize

…medicines to approve for reimbursement, and at what price. As higher–cost medicines put increasing pressure on public health care budgets [3], the need to identify ‘fair’ prices for medicines has never been…

Canberra Hypothesis: the Economics of the Prescription Medicine Market

1 July 1975

The burden of this paper was that it was a fundamental misconception to believe that price competition was lacking in the prescription medicine market, at least in the context of…

Question of Balance: the Benefits and Risks of Pharmaceutical Innovation

1 May 1980

…in which damages have been awarded because a medicine taken during pregnancy was… Since this monograph was completed, two new stories concerning the safety of medicines have been featured prominently…

A global landscape analysis of access to tumour-agnostic therapies 

1 December 2025

Share this: Download publication Henry Fong Priscila Radu Nadine Henderson Martina Garau Lotte Steuten Key messages Tumour-agnostic (TA) therapies disrupt conventional oncology paradigms by targeting molecular alterations rather than tumour…